Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Angina Pectoris Drugs Market from 2024 to 2025?

The market for angina pectoris medications has seen robust growth in the recent past. The market size is projected to increase from $12.32 billion in 2024 to $12.94 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.1%. Factors such as a high occurrence of cardiovascular illnesses, aging population, lifestyle-related factors, a surge in hypertension rates, and prevalence of diabetes have contributed to the growth observed in the historical period.

What Is the Projected Market Size of the Angina Pectoris Drugs Market?

The market for angina pectoris medications is anticipated to witness substantial growth in the coming years, expanding to “$16.55 billion in 2029, with a compound annual growth rate (CAGR) of 6.3%. This predicted growth in the forecast period could be driven by factors such as increasing worldwide obesity figures, progressive precision medicine, a proactive approach towards cardiology, patient learning initiatives, and exploration of new potential treatment targets. The forecast period is also likely to see significant trends such as the use of telemedicine for distant monitoring, real-world data and outcome-based studies, patient-centered medication education, strategic collaborations to enhance market access, progressive regulatory developments, and speedy approvals.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp

Who are the Major Competitors in the Angina Pectoris Drugs Market Outlook?

Major companies operating in the angina pectoris drugs market include Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AERIE PHARMACEUTICALS INC., AbbVie Inc., Amgen Inc., Gilead Sciences Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Ipsen S.A., Lupin Pharmaceuticals Inc., Merck KGaA, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Servier Laboratories, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A.

What Is Fueling Growth in the Angina Pectoris Drugs Market?

The escalating occurrence of cardiovascular conditions is anticipated to boost the expansion of the angina pectoris drug market. A diverse range of disorders that influence the heart and blood vessels fall under cardiovascular diseases, encompassing complications such as coronary artery disease, elevated blood pressure, heart failure, and stroke. The escalating occurrence of cardiovascular ailments can be ascribed to multiple factors, including an elderly population, unhealthy living habits, and the obesity crisis. Medications for angina pectoris, including nitrates, beta-blockers, and calcium channel blockers, efficiently alleviate chest discomfort and pain caused by deficient blood supply to the heart, thereby significantly improving the patient’s overall wellbeing. For instance, in September 2024, data released by the British Heart Foundation, a cardiovascular research charity in the UK, indicated that roughly 7.6 million individuals in the UK are suffering from heart and circulatory conditions, with approximately 4 million males and 3.6 million females living with these diseases. These ailments account for nearly 27% of all deaths in the UK, translating to more than 170,000 deaths per year, or approximately 480 deaths each day, totaling to one death every three minutes. Hence, the escalating occurrence of cardiovascular conditions is propelling the expansion of the angina pectoris drug market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10797&type=smp

Which Angina Pectoris Drugs Market Segments Are Growing the Fastest?

The angina pectoris drugs market covered in this report is segmented –

1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs

2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina

3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates

2) By Antiplatelet Agents: Aspirin, Clopidogrel

3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers

4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers

5) By Anti-Ischemic Agents: Ranolazine, Ivabradine

6) By Statins: Atorvastatin, Rosuvastatin

Which Industry Trends Are Shaping the Future of the Angina Pectoris Drugs Market?

The angina pectoris drugs market is increasingly witnessing the trend of product innovation. To maintain their market position, key pharmaceutical corporations in this sphere are incorporating cutting-edge technologies. Illustrative of this, in March 2023, Hikma Pharmaceuticals PLC, a company based in the UK, introduced a prefilled syringe of Labetalol Hydrochloride Injection, USP. This product has received the green light from the United States Food and Drug Administration. In a hospital setting, the 10 mg/2 mL PFS is used to combat serious hypertension and reduce blood pressure.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Which Countries Are Leading the Angina Pectoris Drugs Market?

North America was the largest region in the angina pectoris drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10797

This Report Delivers Insight On:

1. How big is the angina pectoris drugs market, and how is it changing globally?

2. Who are the major companies in the angina pectoris drugs market, and how are they performing?

3. What are the key opportunities and risks in the angina pectoris drugs market right now?

4. Which products or customer segments are growing the most in the angina pectoris drugs market?

5. What factors are helping or slowing down the growth of the angina pectoris drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model